Outcome Capital has been following the pharma services market dynamics for the past 5 years. The authors believe that this fragmented segment will give way to greater consolidation by both financial buyers looking to roll up smaller players and larger contract research organizations seeking to expand into value-added specialty service areas. Adding to this consolidation is a tepid fund-raising environment, opening the door for financial buyers to play a role in consolidating many niche players.
Published in PharmTech
Authors: Craig A. Steger, Thomas J. Joyce, and Oded Ben-Joseph
Abstract:
Outcome Capital has been following the pharma services market dynamics for the past 5 years. The authors believe that this fragmented segment will give way to greater consolidation by both financial buyers looking to roll up smaller players and larger contract research organizations seeking to expand into value-added specialty service areas. Adding to this consolidation is a tepid fund-raising environment, opening the door for financial buyers to play a role in consolidating many niche players.
The New Orleans biotech is currently raising a tiny $8 million Series A to develop its non-opioid painkiller. It keeps costs low by paying employees cash on an hourly basis—but no salaries.
Read MoreOutcome Capital Life Science Market Pulse March 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?